UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 483

Sortiert nach

Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer

Nature communications, 2018-11, Vol.9 (1), p.4664-5, Article 4664

2018

Link zum Volltext

Verfügbarkeit prüfen

Susac’s syndrome as an immune-related adverse event after pembrolizumab: a case report

Journal of neurology, 2020, Vol.267 (1), p.282-284

2020

Link zum Volltext

Verfügbarkeit prüfen

Repeatability of Radiomic Features in Non-Small-Cell Lung Cancer [18F]FDG-PET/CT Studies: Impact of Reconstruction and Delineation

Molecular imaging and biology, 2016-10, Vol.18 (5), p.788-795

2016

Link zum Volltext

Verfügbarkeit prüfen

Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications

Therapeutic Advances in Medical Oncology, 2017-01, Vol.9 (1), p.46-58

2017

Link zum Volltext

Verfügbarkeit prüfen

Exposure–Response Analysis of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer Patients in a Real-Life Setting

Pharmaceutical research, 2022-10, Vol.39 (10), p.2507-2514

2022

Link zum Volltext

Verfügbarkeit prüfen

Early response evaluation of PD-1 blockade in NSCLC patients through FDG-PET-CT and T cell profiling of tumor-draining lymph nodes

Oncoimmunology, 2023, Vol.12 (1), p.2204745-2204745

2023

Link zum Volltext

Verfügbarkeit prüfen

Dichotomous ALK-IHC Is a Better Predictor for ALK Inhibition Outcome than Traditional ALK-FISH in Advanced Non-Small Cell Lung Cancer

Clinical cancer research, 2017-08, Vol.23 (15), p.4251-4258

2017

Link zum Volltext

Verfügbarkeit prüfen

A two-center comparative study of gastric pull-up and jejunal interposition for long gap esophageal atresia

Journal of pediatric surgery, 2015-04, Vol.50 (4), p.535-539

2015

Link zum Volltext

Verfügbarkeit prüfen

Clinical Relevance of High Plasma Trough Levels of the Kinase Inhibitors Crizotinib, Alectinib, Osimertinib, Dabrafenib, and Trametinib in NSCLC Patients

Therapeutic drug monitoring, 2024-02, Vol.46 (1), p.73

2024

Link zum Volltext

Verfügbarkeit prüfen

Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer

European journal of cancer (1990), 2022-08, Vol.171, p.114-123

2022

Link zum Volltext

Verfügbarkeit prüfen

89Zr-Immuno-PET with Immune Checkpoint Inhibitors: Measuring Target Engagement in Healthy Organs

Cancers, 2023-11, Vol.15 (23), p.5546

2023

Link zum Volltext

Verfügbarkeit prüfen

Response Prediction and Evaluation Using PET in Patients with Solid Tumors Treated with Immunotherapy

Cancers, 2021-06, Vol.13 (12), p.3083

2021

Link zum Volltext

Verfügbarkeit prüfen

Verapamil reduces tachycardia-induced electrical remodeling of the atria

Circulation (New York, N.Y.), 1997-04, Vol.95 (7), p.1945-1953

1997

Link zum Volltext

Verfügbarkeit prüfen

Biliary Atresia in The Netherlands: Outcome of Patients Diagnosed between 1987 and 2008

The Journal of pediatrics, 2012-04, Vol.160 (4), p.638-644.e2

2012

Link zum Volltext

Verfügbarkeit prüfen

Repeatability of [18F]FDG PET/CT total metabolic active tumour volume and total tumour burden in NSCLC patients

EJNMMI research, 2019-02, Vol.9 (1), p.14-12, Article 14

2019

Link zum Volltext

Verfügbarkeit prüfen

Relationship between Biodistribution and Tracer Kinetics of 11C-Erlotinib, 18F-Afatinib and 11C-Osimertinib and Image Quality Evaluation Using Pharmacokinetic/Pharmacodynamic Analysis in Advanced Stage Non-Small Cell Lung Cancer Patients

Diagnostics (Basel), 2022-04, Vol.12 (4), p.883

2022

Link zum Volltext

Verfügbarkeit prüfen

Resistance Mechanisms to AZD9291 and Rociletinib-Letter

Clinical cancer research, 2017-07, Vol.23 (14), p.3966-3966

2017

Link zum Volltext

Verfügbarkeit prüfen

Nonsmall cell lung carcinoma: diagnostic difficulties in small biopsies and cytological specimens

European respiratory review, 2017-09, Vol.26 (144)

2017

Link zum Volltext

Verfügbarkeit prüfen

The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs

Nature (London), 2019-10, Vol.574 (7776), p.127-131

2019

Link zum Volltext

Verfügbarkeit prüfen

Representativeness of Phase III Trial for Osimertinib in Pretreated Advanced EGFR-Mutated Non-small-cell Lung Cancer Patients and Treatment Outcomes in Clinical Practice

Targeted oncology, 2022-01, Vol.17 (1), p.53-59

2022

Link zum Volltext

Verfügbarkeit prüfen

Hypofractionated radiotherapy combined with targeted therapy or immunotherapy: Dutch survey on current practice, knowledge and challenges

Clinical and translational radiation oncology, 2022-03, Vol.33, p.93-98

2022

Link zum Volltext

Verfügbarkeit prüfen

Real-World Approach for Molecular Analysis of Acquired EGFR Tyrosine Kinase Inhibitor Resistance Mechanisms in NSCLC

JTO clinical and research reports, 2021-12, Vol.2 (12), p.100252-100252, Article 100252

2021

Link zum Volltext

Verfügbarkeit prüfen

Outcomes of Hypofractionated High-Dose Radiotherapy in Poor-Risk Patients with “Ultracentral” Non–Small Cell Lung Cancer

Journal of thoracic oncology, 2016-07, Vol.11 (7), p.1081-1089

2016

Link zum Volltext

Verfügbarkeit prüfen

Stage I non-small cell lung cancer: Treatment modalities, Dutch daily practice and future perspectives

Cancer treatment and research communications, 2021, Vol.28, p.100404-100404, Article 100404

2021

Link zum Volltext

Verfügbarkeit prüfen

Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung cancer: clinical impact of alectinib

OncoTargets and therapy, 2017-01, Vol.10, p.4535-4541

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 483

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(403)
Mit Volltextzugriff
(417)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(5)
... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer

Susac’s syndrome as an immune-related adverse event after pembrolizumab: a case report

Repeatability of Radiomic Features in Non-Small-Cell Lung Cancer [18F]FDG-PET/CT Studies: Impact of Reconstruction and Delineation

Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications

Exposure–Response Analysis of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer Patients in a Real-Life Setting

Early response evaluation of PD-1 blockade in NSCLC patients through FDG-PET-CT and T cell profiling of tumor-draining lymph nodes

Dichotomous ALK-IHC Is a Better Predictor for ALK Inhibition Outcome than Traditional ALK-FISH in Advanced Non-Small Cell Lung Cancer

A two-center comparative study of gastric pull-up and jejunal interposition for long gap esophageal atresia

Clinical Relevance of High Plasma Trough Levels of the Kinase Inhibitors Crizotinib, Alectinib, Osimertinib, Dabrafenib, and Trametinib in NSCLC Patients

Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer

89Zr-Immuno-PET with Immune Checkpoint Inhibitors: Measuring Target Engagement in Healthy Organs

Response Prediction and Evaluation Using PET in Patients with Solid Tumors Treated with Immunotherapy

Verapamil reduces tachycardia-induced electrical remodeling of the atria

Biliary Atresia in The Netherlands: Outcome of Patients Diagnosed between 1987 and 2008

Repeatability of [18F]FDG PET/CT total metabolic active tumour volume and total tumour burden in NSCLC patients

Relationship between Biodistribution and Tracer Kinetics of 11C-Erlotinib, 18F-Afatinib and 11C-Osimertinib and Image Quality Evaluation Using Pharmacokinetic/Pharmacodynamic Analysis in Advanced Stage Non-Small Cell Lung Cancer Patients

Resistance Mechanisms to AZD9291 and Rociletinib-Letter

Nonsmall cell lung carcinoma: diagnostic difficulties in small biopsies and cytological specimens

The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs

Representativeness of Phase III Trial for Osimertinib in Pretreated Advanced EGFR-Mutated Non-small-cell Lung Cancer Patients and Treatment Outcomes in Clinical Practice

Hypofractionated radiotherapy combined with targeted therapy or immunotherapy: Dutch survey on current practice, knowledge and challenges

Real-World Approach for Molecular Analysis of Acquired EGFR Tyrosine Kinase Inhibitor Resistance Mechanisms in NSCLC

Outcomes of Hypofractionated High-Dose Radiotherapy in Poor-Risk Patients with “Ultracentral” Non–Small Cell Lung Cancer

Stage I non-small cell lung cancer: Treatment modalities, Dutch daily practice and future perspectives

Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung cancer: clinical impact of alectinib

Suchergebnisse filtern